From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver Pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and business process infrastructure for market access and therapy commercialization.
Solutions overview
IntegriChain delivers pharma’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the pharmaceutical industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, Market Access experts, analysts, technologies, and advisory professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
August 11, 2020 | 1:00 pm ET
On June 17, 2020, The Centers for Medicare & Medicaid Services (CMS) posted a proposed rule that could impact manufacturers’ Medicaid and 340B liabilities, commercial strategies, and patient assistance programs. At a high level, this proposed rule may:
In this webinar, we will attempt to demystify the potential impact the proposed rule may have on a participating manufacturer’s business. We will share insights and perspectives from the multitude of discussions we have had with manufacturers since the proposed rule was released and highlight some of the key questions that the proposed rule raises. We will also walk through several “real world” examples of how some of these proposed changes may impact a manufacturer’s business to explore the potential application of the more impactful aspects of the proposed rule.
Please join Rupal Patel, Director, Advisory Services and Carmela Crimeni, Director, Advisory Services.
Rupal Patel Carmela Crimeni
Register now!